FDA's Proposal on Obesity Drugs Raises Industry Concerns Amid AstraZeneca Setbacks
The FDA's recent proposal to exclude active ingredients in obesity drugs from the compounding list has sparked significant concerns within the industry, coinciding with AstraZeneca's challenges in drug development.
Editorial Staff 8 days ago